Phase Ib/IIa Trial With AC01 in Patients With HFrEF

NCT ID: NCT05642507

Last Updated: 2025-11-17

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 58 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-02-23
• Study Completion Date: 2025-10-27

Brief Summary

This is a randomized, double-blind, placebo-controlled two-part study with a multiple escalating dose phase followed by a cohort expansion phase to assess safety, tolerability, pharmacokinetics and pharmacodynamics of AC01 in patients with heart failure with reduced ejection fraction (HFrEF).

Detailed Description

During the dose escalation phase, patients will be given AC01 orally twice daily for seven days. In the cohort expansion phase, patients will be given AC01 orally twice daily for 28 days at dose levels selected on the basis of results of the dose escalation phase.

Conditions

Heart Failure With Reduced Ejection Fraction

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Active (AC01) Microtablets

Escalating doses of AC01

Group Type: EXPERIMENTAL

AC01

Intervention Type: DRUG

AC01 microtablets

Placebo Microtablets

Matching placebo tablets

Group Type: PLACEBO_COMPARATOR

AC01

Intervention Type: DRUG

AC01 microtablets

Interventions

AC01

AC01 microtablets

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Male and female out-patients of any ethnicity, between 18-80 years (inclusive), with stable HFrEF.
• Chronic HF for at least 6 months duration defined by history with current NYHA class II-III severity.
• LVEF ≤40% by TTE more than 6 months before screening and again at screening (screening measurement confirmed by echocardiography core lab).
• Sinus rhythm with mean resting heart rate 55-90 bpm.
• Cardiac Index 0.5-2.4 measured by Innocor at screening and Day -1. Screening measurement confirmed by core lab.
• Transvenous ICD for primary prevention in place and active (as long as it is not subcutaneous).
• Optimal guideline-based medical therapy for HFrEF as judged by the Investigator, at stable doses for ≥2 weeks with no intention to change dosing during trial duration.

Exclusion Criteria

• Any cardiac rhythm that does or could interfere with ECG or TTE interpretation, including but not limited to permanent or persistent atrial fibrillation or flutter or paroxysmal atrial fibrillation or flutter with an episode in the last 3 months, frequent premature ventricular contractions, or atrial or ventricular pacing
• Ongoing or planned mechanical circulatory support, treatment with any IV vasoactive drugs (vasodilators, inotropes, or vasopressors) or diuretics, and/or dialysis or hemofiltration or ultrafiltration.
• Probable alternative explanations for symptoms or signs (e.g., but not limited to, known primary cardiomyopathy [hypertrophic, constrictive, restrictive, infiltrative, congenital]). Primary uncorrected hemodynamically significant valve disease, right-sided HF not due to left-sided HF.
• History of aborted cardiac arrest and/or ICD for secondary prevention.
• Hospitalized for HF or received IV diuretics, vasodilators, or inotropes for HF ≤30 days.
• Clinical diagnosis of acute coronary syndrome or stroke ≤30 days.
• PCI or percutaneous valve intervention ≤30 days or planned.
• Angina pectoris ≤30 days.
• Any cardiovascular procedure planned during study duration.
• Hospitalized or unplanned visit to the emergency department for any reason in last 30 days; patient is eligible 30 days from discharge from hospital.
• Use of any drugs or substances known to be strong inducers of CYP3A4 enzyme within 28 days prior to the dosing day and/or planned to be used during the overall study period.
• eGFR by CKD-EPI <30 mL/min/1.73 m2 at screening or at Day -1.
• Serum or plasma potassium <3.5 or >5.2 mEq/L at screening or at Day -1. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >3 times upper limit of normal (ULN) or total bilirubin >2 times ULN at screening or at Day -1. Or known cirrhosis or severe liver or pancreatic disease, or Gilbert's syndrome.
• Any condition that in the opinion of the Investigator may interfere with adherence to the protocol.
• Systolic blood pressure <90 mmHg or >140 mmHg at screening or at Day-1.
• Any of the following ECG findings: atrial or ventricular pacing, QTcF >450 ms, AV block I with PQ > 240 ms, AV block II or III at screening and at Day -1. In the case of non-paced QRS prolongation >120 ms, or if CRT is determined to be required and is actively pacing the ventricles, the QTcF is allowed to be up to but not greater than 470 ms.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

AnaCardio AB

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Lars Lund, MD PhD

Role: STUDY_CHAIR

AnaCardio AB

Locations

Spedali Civilia di Brescia

Brescia, , Italy

Azienda Sanitaria Universitaria Integrata

Trieste, , Italy

Amsterdam University Medical Centre

Amsterdam, , Netherlands

University Medical Centre Groningen/ICON

Groningen, , Netherlands

Maastricht Heart and Vascular Center

Maastricht, , Netherlands

Erasmus Medical Centre

Rotterdam, , Netherlands

Sahlgrenska University Hospital

Gothenburg, , Sweden

Skånes Universitetssjukhus Lund

Lund, , Sweden

Karolinska University Hospital

Stockholm, , Sweden

Ninewells Hospital and Medical School

Dundee, , United Kingdom

University of Glasgow, Institute of Cardiovascular & Medical Sciences

Glasgow, , United Kingdom

Golden Jubilee National Hospital

Glasgow, , United Kingdom

King's College Hospital

London, , United Kingdom

Countries

Italy; Netherlands; Sweden; United Kingdom

Other Identifiers

AC01-01

Identifier Type: -

Identifier Source: org_study_id